Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD2269 in Metastatic Castration Resistant Prostate Cancer
NCT04634344Phase 1Terminated
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Apr 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of DZD2269 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Adverse Events, Serious Adverse Events and 1 more. Started Apr 2021; status: terminated.
02
Drugs
DZD2269
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04634344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634344.